Oct 7, 2026 07:00AM
Oct 7, 2026 07:00AM
Oct 1, 2026 04:01PM
Oct 1, 2026 04:01PM
Sep 29, 2026 04:01PM
Sep 28, 2026 07:00AM
Sep 28, 2026 07:00AM Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
Sep 3, 2026 04:01PM
Sep 1, 2026 04:01PM
Sep 1, 2026 09:07AM
Aug 4, 2026 07:00AM
Jul 28, 2026 07:00AM
Jun 4, 2026 08:00AM
May 29, 2026 04:01PM Arvinas to Present at Jefferies Global Healthcare Conference
May 12, 2026 07:05AM
May 12, 2026 07:01AM
May 12, 2026 07:00AM
May 12, 2026 07:00AM
May 5, 2026 07:00AM
May 1, 2026 03:39PM
May 1, 2026 01:12PM Arvinas shares gain as FDA approves breast cancer drug Veppanu
May 1, 2026 12:43PM
May 1, 2026 12:43PM
Feb 24, 2026 07:00AM
Dec 21, 2025 04:00AM
Nov 24, 2025 07:02AM
Nov 24, 2025 07:00AM
Nov 5, 2025 07:00AM Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 20, 2025 04:15AM
Oct 13, 2025 07:00AM
Sep 24, 2025 02:35AM
Sep 19, 2025 04:47AM
Sep 17, 2025 04:31PM
Sep 17, 2025 04:30PM
Aug 8, 2025 04:05PM FDA accepts Arvinas drug application for advanced breast cancer treatment
Aug 8, 2025 04:05PM
Aug 6, 2025 07:00AM
Jun 11, 2025 08:30AM
Jun 6, 2025 08:38AM
Jun 6, 2025 07:01AM
Jun 6, 2025 07:00AM
May 31, 2025 08:00AM Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
May 31, 2025 08:00AM
May 1, 2025 07:00AM
Apr 23, 2025 10:45AM
Apr 23, 2025 10:44AM
Apr 9, 2025 09:34AM
Mar 11, 2025 06:46AM
Mar 11, 2025 06:45AM Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
Feb 11, 2025 07:00AM

333,665 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All